Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study

The Eye Hospital of Wenzhou Medical University300 enrolled

Overview

To evaluate the correlation between macular pigment optical density (MPOD) levels and risk of progression in patients with age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly.\[1\] The disease is categorized into early, intermediate, or advanced stages based on the severity of symptoms. The advanced stage, including GA and CNV, involves central region of the retina, which leads to a gradual or rapid loss of photoreceptors and central vision. The macular pigment (MP) consists of xanthophyll, which is formed from the yellow carotenoid lutein, zeaxanthin, and meso-zeaxanthin.These pigments play an important role in protecting the retina against oxidative stress through different mechanisms\[6\]. Many studies have shown a various association of AMD and MP.Blue Mountain Eye Study revealed low dietary intake of lutein and zeaxanthin is associated with a higher risk of AMD. However, dry and wet subtypes of AMD may have different etiologies and risk factors. Little is known whether longitudinal study of macular pigment optical density (MPOD) is related to AMD progression. A comprehensive ophthalmologic examination including fundus photography,OCT and MPOD was performed at baseline, and semiannually thereafter for 3 years. Fundus reflectance (VISUCAM 500, reflectance of a single 460 nm wavelength) was used to measure the MPOD levels. Associated risk factors including body-mass index (BMI), smoking, diet, and cardiovascular diseases were documented. Drusen characteristics (size, type, area), pigmentary abnormalities (increased pigment, depigmentation, geographic atrophy), and presence of abnormalities characteristic of neovascular AMD were graded. For estimations of AMD progression , a 9-step severity scale that combines a 6-step drusen area scale with a 5-step pigmentary abnormality scale is used. In this study, we are going to investigate a 3-year study of incidence and progression for AMD and associated risk factors, in a population-based cohort of Chinese aged 45 years and older living in the city of Wenzhou.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Macular Pigment Optical Density

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * subject is diagnosed with either CNV, dry AMD * 45 years of age or older * provides signed and dated informed consent Exclusion Criteria: * Ocular condition in the study eye which may impact vision and confound study outcomes * Presence of macular edema like retinal vascular diseases or diabetic retinopathy * active inflammation ofr infection in the study eye * high myopia（ ≥6D ）

Locations (1)

The eye hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

Association between changes of macular pigment optical density (MPOD) level and incidence rates of advanced AMD

Incident advanced AMD was evaluated based on the AMD grade at the end of the clinical trial with follow-up time of 3 years. Progressors were those individuals with early or intermediate AMD at baseline who progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progressed to advanced AMD in both eyes

Time frame: from baseline to month 36

Secondary Outcomes

Association between age and incident Advanced AMD

controlling for age (70 years or older versus younger than 70)

Time frame: baseline

Association between gender and incident Advanced AMD

Time frame: baseline

Association between Baseline AMD grade and incident Advanced AMD

Baseline AMD grade was deﬁned as AREDS category 1 in both eyes (essentially free of age-related macular abnormalities), category 2 in the worst eye (mild changes including multiple small drusen, nonextensive intermediate drusen, and/or pigment abnormalities), category 3 in the worst eye (at least one large drusen of at least 125µm diameter, extensive intermediate drusen, and/or noncentral geographic atrophy), category 4 in one eye (advanced AMD, either neovascular or central geographic atrophy, or visual loss due to AMD regardless of phenotype), or category 4 in both eyes.

Time frame: baseline

Association between cigarette smoking and incident Advanced AMD

cigarette smoking information was acquired by questionaires(never, past, or current) .

Time frame: baseline

Association between body mass index (BMI) and incident Advanced AMD

Central Contacts

Rong Zhou, MD

CONTACT

86-577-88068855 zhourongmoon@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.